The regulatory landscape for ethanol-based biocidal products in Europe is entering a significant new phase. Following years of scientific evaluation and regulatory discussion, the adoption of the opinion on ethanol as an active substance under Product-Types (PT) 1, 2 and 4 marks a significant milestone for manufacturers placing ethanol-based biocidal products on the EU market.
While the European Commission’s final approval process is still to come, the direction of travel is becoming much clearer. For companies developing or marketing ethanol-based biocidal products, the focus should now shift from monitoring regulatory developments to preparing for authorisation under the Biocidal Products Regulation (BPR). Businesses that begin planning now will be better placed to avoid delays, maintain market access, and respond confidently when the new requirements take effect
From Regulatory Uncertainty to Business Readiness
The evaluation of ethanol has been one of the longest-running active substance assessments under the European biocides regulatory framework. Originally submitted in 2007 under Directive 98/8/EC, the process continued through the transition to the BPR and was significantly extended while regulatory discussions on harmonised classification under the CLP Regulation delayed progress.
While some regulatory questions remain, particularly regarding future classification discussions, the adoption of the Biocidal Products Committee’s opinion provides manufacturers with greater certainty than they have had for many years. Rather than waiting for the final legislative steps, businesses should use this period to assess their portfolios, identify regulatory gaps and begin preparing data required for product authorisation.
Why Preparation Matters Now
Obtaining a biocidal product authorisation involves far more than selecting an approved active substance. Preparing a compliant biocidal product dossier involves careful planning and technical evidence, including but not limited to:
- Product formulation reviews
- Efficacy testing across relevant Product-Types (PT1, PT2 and PT4 where applicable)
- Packaging compatibility assessments
- Stability studies
- Human health and environmental considerations
- A long-term authorisation strategy
Many of these activities take months to complete, and some studies cannot be accelerated. Starting early helps reduce regulatory risk, avoid unnecessary delays, and ensures products are ready for submission once authorisation deadlines are confirmed.
Building Smarter Product Portfolios
One of the key strategic decisions that is important to make early is whether to authorise individual products or develop broader product families.
For some manufacturers, a single-product approach offers a more straightforward route to market. While others may benefit from a product family approach, allowing for greater flexibility by covering multiple physical forms, such as gels, sprays, wipes, and aerosols, to be covered within a single authorisation where the regulatory criteria are met. Each approach presents different technical, regulatory, and commercial considerations.
Making this decision early can reduce future development costs, simplify regulatory management, and provide greater flexibility as portfolios expand.
Collaboration Can Reduce Time, Cost, and Duplication
As regulatory requirements become increasingly complex and costly, collaborative approaches are becoming an attractive option for many manufacturers, particularly SMEs.
Sharing activities such as formulation development, efficacy studies, and dossier preparation, can significantly reduce duplicated work and development costs while allowing each company to maintain its own commercial identity. A collaborative regulatory strategy can provide access to high-quality data packages that might otherwise be difficult or expensive to generate independently.
How CIRS
Can Support Your Ethanol Biocidal Product Strategy
Preparing for ethanol biocidal product authorisation requires more than regulatory knowledge – it requires a clear strategy and the right technical support.
At CIRS
, we work with manufacturers throughout the product life cycle, providing regulatory and scientific support for biocidal products across the EU. Our biocides services include, but are not limited to:
- Regulatory strategy and portfolio assessments;
- Biocidal Product authorisation planning;
- Biocidal Product Family strategy;
- Dossier preparation and submission;
- Efficacy testing coordination;
- Regulatory data gap analysis (DGA);
- Collaborative regulatory projects and data-sharing initiatives; and
- Ongoing compliance support.
Whether you are preparing a new ethanol-based disinfectant for the European market or reviewing an existing portfolio, early planning can help minimize regulatory risk and create a more efficient route to authorisation.
Looking Ahead
The coming months and years will be critical for manufacturers of ethanol-based biocidal products. Businesses that begin preparing now will be in a far stronger position than those waiting for the final regulatory milestones.
Success under the evolving EU Biocidal Products Regulation will depend on combining regulatory expertise with practical planning, robust scientific data and a well-defined authorisation strategy. By taking action early, manufacturers can protect market access, reduce development timelines, and be ready to respond as the regulatory framework continues to evolve.
If you need any assistance or have any questions, please get in touch with us
We have launched a LinkedIn newsletter to keep you up to date on the latest developments across the chemical industry including food and FCMs and personal and home care.
Previous: EU PPWR: What Packaging Businesses Need to Do Now
Next: Japan NITE Releases FY2025 GHS Classification Results for 142 Substances
